Latest BLLN news

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

GlobeNewsWire · Wed, 14 Oct 2026 08:05:00 -0400

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials

Seeking Alpha · Mon, 12 Oct 2026 22:41:49 -0400

BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average of 22%.

BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

GlobeNewsWire · Wed, 07 Oct 2026 07:00:00 -0400

Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

Benzinga · Wed, 23 Sep 2026 14:09:44 -0400

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.

BillionToOne SVP Sells 1,416 Shares

The Motley Fool · Mon, 21 Sep 2026 08:56:01 -0400

The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

The Motley Fool · Thu, 17 Sep 2026 13:15:47 -0400

The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a portion belonging to his spouse.

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

PRNewsWire · Wed, 02 Sep 2026 16:05:00 -0400

MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.

Market information is provided for research and visualization and is not investment advice.